Skip to Main content Skip to Navigation
Preprints, Working Papers, ...

Development of an in-house Quantitative ELISA for the Evaluation of Different Covid-19 Vaccines in Human

Abstract : Purpose: Reliable serological assays are needed to understand the real impact of COVID-19. In order to compare the e ciency of different COVID-19 vaccines used in the National Vaccination Program in Tunisia, we have developed a quantitative in-house ELISA. Methods: The ELISA is based on the ectodomain of the SARS-CoV-2 Spike Baculovirus recombinant protein. We have used a panel of 145 COVID-19 RT-PCR positive serum samples and 116 pre-pandemic serum samples as a negative panel. The validation was carried out by comparison to four commercial techniques (Vidas® SARS-CoV-2 IgG anti-RBD Biomérieux®, Elecsys® Anti-Nucleocapsid of SARS-CoV-2 Roche®, cPass® GenScript® and the quantitative Elecsys® Anti-RBD of SARS-CoV-2, Roche®). For the evaluation of the National Vaccination campaign, we have included 115 recipients of one of the different used vaccines. Results: The qualitative performances of the developed ELISA gave 96% sensitivity, 97.5% speci city and 0.968 accuracy. For the evaluation of the different brand of vaccines in recipients not previously infected with SARS-CoV-2, it seems that mRNA vaccine of P zer/BioNTech has shown a higher e cacy compared to inactivated virus vaccines. COVID-19 convalescent individuals have generated poor antibody responses. Nevertheless, when they are vaccinated with any brand of the COVID-19 vaccines, many of them mounted an exponential increase of the induced immune responses, quali ed as a "hybrid vigor immunity". Conclusion: Our developed in-house ELISA seems to be very e cient in evaluating the effectiveness of anti-COVID-19 vaccination. Platforms based on mRNA vaccine are better performing than that based on inactivated virus.
Document type :
Preprints, Working Papers, ...
Complete list of metadata

https://hal-riip.archives-ouvertes.fr/pasteur-03542087
Contributor : AbdelHakim Ben Hassine Connect in order to contact the contributor
Submitted on : Tuesday, January 25, 2022 - 10:26:16 AM
Last modification on : Tuesday, January 25, 2022 - 10:48:36 AM
Long-term archiving on: : Tuesday, April 26, 2022 - 6:53:04 PM

File

bbnn.pdf
Files produced by the author(s)

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Collections

Citation

Mariem Gdoura, Fatma Ben Ghaloum, Meriem Ben Hamida, Wafa Chamsa, Henda Triki, et al.. Development of an in-house Quantitative ELISA for the Evaluation of Different Covid-19 Vaccines in Human. 2022. ⟨pasteur-03542087⟩

Share

Metrics

Record views

127

Files downloads

15